AbbVie Inc. (ABBV) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 41.64B USD | Liabilities, Current |
| Cash and equivalents | 6.57B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 13.82B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 5.13B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $41.64B | $6.57B | (m) | $13.82B | $5.13B | (m) |
| 2026-03-31 | (m) | $42.10B | $9.39B | (m) | $12.48B | $5.05B | (m) |
| 2025-12-31 | (m) | $43.29B | $5.23B | (m) | $12.59B | $4.95B | (m) |
| 2025-09-30 | (m) | $39.39B | $5.63B | (m) | $12.77B | $4.94B | (m) |
| 2025-06-30 | (m) | $39.77B | $6.47B | (m) | $12.64B | $4.96B | (m) |
| 2025-03-31 | (m) | $36.40B | $5.17B | (m) | $12.48B | $4.53B | (m) |
| 2024-12-31 | (m) | $38.75B | $5.52B | (m) | $10.92B | $4.18B | (m) |
| 2024-09-30 | (m) | $43.06B | $7.26B | (m) | $11.47B | $4.45B | (m) |
| 2024-06-30 | (m) | $41.91B | $13.13B | (m) | $11.72B | $4.22B | (m) |
| 2024-03-31 | (m) | $41.52B | $18.07B | (m) | $11.95B | $4.25B | (m) |
| 2023-12-31 | (m) | $37.84B | $12.81B | (m) | $11.15B | $4.10B | (m) |
| 2023-09-30 | (m) | $34.77B | $13.29B | (m) | $11.41B | $3.98B | (m) |
| 2023-06-30 | (m) | $32.24B | $8.76B | (m) | $11.49B | $4.05B | (m) |
| 2023-03-31 | (m) | $27.59B | $6.71B | (m) | $11.47B | $3.83B | (m) |
| 2022-12-31 | (m) | $29.54B | $9.20B | (m) | $11.25B | $3.58B | (m) |
| 2022-09-30 | (m) | $32.71B | $11.83B | (m) | $10.74B | $3.17B | (m) |
| 2022-06-30 | (m) | $34.47B | $8.52B | (m) | $11.24B | $3.40B | (m) |
| 2022-03-31 | (m) | $32.52B | $6.10B | (m) | $10.73B | $3.48B | (m) |
| 2021-12-31 | (m) | $35.19B | $9.75B | (m) | $9.98B | $3.13B | (m) |
| 2021-09-30 | (m) | $28.53B | $12.18B | (m) | $9.28B | $3.09B | (m) |
| 2021-06-30 | (m) | $28.68B | $8.55B | (m) | $9.91B | $3.39B | (m) |
| 2021-03-31 | (m) | $31.95B | $9.76B | (m) | $9.59B | $3.27B | (m) |
| 2020-12-31 | (m) | $28.66B | $8.45B | (m) | $8.82B | $3.31B | (m) |
| 2020-09-30 | (m) | $24.18B | $7.89B | (m) | $8.42B | $3.47B | (m) |
| 2020-06-30 | (m) | $24.65B | $6.02B | (m) | $8.35B | $4.06B | (m) |
| 2020-03-31 | (m) | $16.47B | $41.14B | (m) | $6.36B | $1.84B | (m) |
| 2019-12-31 | (m) | $15.59B | $39.92B | (m) | $5.43B | $1.81B | (m) |
| 2019-09-30 | (m) | $17.49B | $10.65B | (m) | $5.53B | $1.93B | (m) |
| 2019-06-30 | (m) | $16.94B | $5.17B | (m) | $5.48B | $1.90B | (m) |
| 2019-03-31 | (m) | $13.90B | $4.90B | (m) | $5.68B | $1.70B | (m) |
| 2018-12-31 | (m) | $17.24B | $7.29B | (m) | $5.38B | $1.60B | (m) |
| 2018-09-30 | (m) | $15.39B | $8.02B | (m) | $5.78B | $1.79B | (m) |
| 2018-06-30 | (m) | $17.22B | $3.55B | (m) | $5.79B | $1.58B | (m) |
| 2018-03-31 | (m) | $17.06B | $9.01B | (m) | $5.84B | $1.74B | (m) |
| 2017-12-31 | (m) | $16.64B | $9.30B | (m) | (m) | $1.60B | (m) |
| 2017-09-30 | (m) | $13.03B | $8.45B | (m) | $4.89B | $1.78B | (m) |
| 2017-06-30 | (m) | $12.26B | $6.09B | (m) | $4.86B | $1.58B | (m) |
| 2017-03-31 | (m) | $8.84B | $4.74B | (m) | $4.68B | $1.43B | (m) |
| 2016-12-31 | (m) | $9.78B | $5.10B | (m) | (m) | $1.44B | (m) |
| 2016-09-30 | (m) | $9.10B | $6.22B | (m) | $5.00B | $1.63B | (m) |
| 2016-06-30 | (m) | $9.27B | $6.33B | (m) | $5.05B | $1.76B | (m) |
| 2016-03-31 | (m) | $10.66B | $7.56B | (m) | $4.75B | $1.79B | (m) |
| 2015-12-31 | (m) | $10.89B | $8.40B | (m) | (m) | $1.72B | (m) |
| 2015-09-30 | (m) | $8.81B | $9.22B | (m) | (m) | $1.84B | (m) |
| 2015-06-30 | (m) | $11.26B | $7.40B | (m) | (m) | $1.62B | (m) |
| 2015-03-31 | (m) | $11.05B | $7.91B | (m) | (m) | $1.02B | (m) |
| 2014-12-31 | (m) | $11.40B | $8.35B | (m) | (m) | $1.12B | (m) |
| 2014-09-30 | (m) | $6.63B | $7.72B | (m) | (m) | $1.01B | (m) |
| 2014-06-30 | (m) | $6.32B | $9.09B | (m) | (m) | $1.05B | (m) |
| 2014-03-31 | (m) | $6.22B | $8.14B | (m) | (m) | $1.10B | (m) |
| 2013-12-31 | (m) | $6.88B | $9.60B | (m) | (m) | $1.15B | (m) |
| 2013-09-30 | (m) | $6.88B | $8.97B | (m) | (m) | $1.17B | (m) |
| 2013-06-30 | (m) | $6.80B | $8.74B | (m) | (m) | $1.08B | (m) |
| 2013-03-31 | (m) | $6.77B | $6.98B | (m) | (m) | $1.04B | (m) |
| 2012-12-31 | (m) | $6.78B | $5.90B | (m) | (m) | $1.09B | (m) |
| 2012-09-30 | (m) | (m) | $2.76B | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | $74.00M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | $41.00M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $27.00M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $10.00M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |